The presence of cancer cells in autografts of breast cancer patients has been described to have prognostic value or directly lead to relapse. Previously, we demonstrated that apheresis products (APs) collected after induction chemotherapy have a significantly lower likelihood of tumor cell contamination. Here, we examine the prognostic value of micrometastases in autografts. Data from 83 patients with breast cancer treated with autologous blood stem cell transplantation were analyzed. Pancytokeratin-FITC conjugated antibodies were used to detect contaminating breast cancer cells in the APs. Progression and survival data analyzed on the basis of three or fewer cancer cells showed no significant differences in outcomes. Of the 83 patients, 11 had more than three cancer cells detectable in their APs. In total, 72 patients were shown to have less than three cells detectable. When patients with more than three cells were compared to patients with 0-3, we found statistically significant differences in progression-free survival. We also found a significant difference in overall survival (OS) between the two groups. No difference was observed in OS since the time of diagnosis. We conclude that patients with more than three contaminating cells in their APs have micrometastases and represent a poor prognosis group.
Summary:
The presence of cancer cells in autografts of breast cancer patients has been described to have prognostic value or directly lead to relapse. Previously, we demonstrated that apheresis products (APs) collected after induction chemotherapy have a significantly lower likelihood of tumor cell contamination. Here, we examine the prognostic value of micrometastases in autografts. Data from 83 patients with breast cancer treated with autologous blood stem cell transplantation were analyzed. Pancytokeratin-FITC conjugated antibodies were used to detect contaminating breast cancer cells in the APs. Progression and survival data analyzed on the basis of three or fewer cancer cells showed no significant differences in outcomes. Of the 83 patients, 11 had more than three cancer cells detectable in their APs. In total, 72 patients were shown to have less than three cells detectable. When patients with more than three cells were compared to patients with 0-3, we found statistically significant differences in progression-free survival. We also found a significant difference in overall survival (OS) between the two groups. No difference was observed in OS since the time of diagnosis. We conclude that patients with more than three contaminating cells in their APs have micrometastases and represent a poor prognosis group. Bone Marrow Transplantation (2003) 32, 307-311. doi:10.1038/sj.bmt.1704133 Keywords: micrometastases; breast cancer; apheresis; cytokeratins The presence of occult tumor cells in peripheral blood or bone marrow of patients with breast cancer has been extensively reported. [1] [2] [3] It has been suggested that the presence of tumor cells in the autograft is responsible at least in part for recurrent disease after autologous transplantation. [4] [5] [6] Further, the presence of cancer cells in autografts (micrometastasis) has also been described to be of prognostic value; however, in breast cancer this is only established for bone marrow. 7 The clinical significance of bone marrow metastases in breast cancer has also been documented. 5 It is known that micrometastases are present in peripheral blood stem cell grafts, and they can even survive high-dose chemotherapy (HDCT). 8 Blood progenitor cells seem to contain fewer tumor cells than bone marrow. [9] [10] [11] [12] However, it is unknown if the number of contaminating cancer cells in the blood progenitor cell population (apheresis product (AP)) correlates with a poorer outcome in terms of progression-free survival (PFS) or overall survival (OS).
A small study by Vannucchi et al 13 examined micrometastases in bone marrow from 33 breast cancer patients using PCR and immunohistochemistry for cytokeratins. They found a trend toward longer relapse-free survival in patients transplanted with negative stem cells, but the difference was not significant. Nevertheless, they suggested that micrometastases-positive patients seemed to represent a poorer prognosis group.
In a previous study, we have shown that APs collected after the second or third cycle of induction chemotherapy (ICT) have a significantly lower likelihood of tumor cell contamination.
14 This previous report on 17 patients in part examined leukopheresis for contaminating breast cancer cells. This small study did not have the statistical power to show significance when either PFS or OS was examined.
Here we explore the prognostic value of micrometastasis in the autografts of patients who underwent ICT and stem cell collection for breast cancer. This is the largest study to date that examines micrometastases in APs and correlates this with clinical outcome (relapse or survival). To determine the presence of contaminating tumor cells, cytokeratin-positive cells were examined. Cytokeratins are expressed in epithelial cells, such as breast cancer cells, and should not normally be present in the blood. This technique has been well established as a method of detection of contaminating tumor cells. 12 
Materials and methods

Patients and treatments
Between January 1995 and November 2000, 83 patients with breast cancer who were undergoing autologous blood stem cell transplantation (ABSCT) were enlisted into this study. All enrolled patients signed an internal review board (IRB) approved consent. Patients were all female and ranged in age from 21 to 65 years. Patient demographics are described in Table 1 .
Induction therapy included anthracyclin combinations. Patients responding to ICT underwent one additional cycle of CT plus G-CSF (300 mg for o70 kg body weight, 480 mg for 70-100 kg, or 600 mg for 4100 kg) starting on day 7. The target to collect was at least 5 Â 10 6 CD34+ cells/kg body weight for each patient. This was continued daily until apheresis was complete. Apheresis was usually performed on day 13 using a Cobe Spectra Cell separator (Cobe Laboratories, Englewood, CO, USA) as previously described. 15 Apheresis was performed when sufficient CD34+ cells were detectable in the blood. Apheresis product was then stored until required. Patients received one of six HDCT regimens (Table 1) . Since patients in both groups utilized a wide range of the HDCT regimens it is unlikely that differences in outcomes are accounted for by the HDCT received.
Cytokeratin staining
A measure of 50 ml of APs was suspended in 150 ml RPMI-1640 with anticoagulant citrate dextrose solution formula A (ACD-A) for a negative control, positive control, and duplicate patient tubes. Fresh or frozen breast tumor cells were used as a positive control. These were fresh surgical specimens received and histologically confirmed in the pathology lab. Cell suspensions were made from the tumor and then frozen in aliquots until required. CD45-PE (Beckman-Coulter, Hialeah, FL, USA) was added to each sample and incubated for 5 min in the dark at room temperature. IntraPrep Reagent A (Beckman-Coulter, Hialeah, FL, USA) was subsequently added. Cells were then washed with 3 ml of PBS, and centrifuged at 250 g for 5 min. The supernatant was discarded and the cells resuspended in IntraPrep Regeant B. A pan-cytokeratin-FITC (Beckman-Coulter, Hialeah, FL, USA) or MsIg-FITC (isotype control) antibody was added as appropriate. After incubation for 15 min at room temperature, cells were washed. The cell pellet was pipetted onto slides and airdried in the dark. Slides were cover-slipped and scanned by fluorescent microscopy. Leukocytes were identified by their fluorescent orange color, and breast cells by their bright green cytoplasmic fluorescence. The number of cytokeratin positive cells/slide was recorded for each patient. Cells 1-1.5 Â 10 6 (denominator) were examined per slide. This was carried out in duplicate, so 2-3 Â 10 6 cells were examined for each case.
Statistical analysis
A log-rank test was used for analyzing progression or survival. Progression was considered to have occurred when either a local or distant relapse was documented or death occurred. Survival was taken as time from initial diagnosis, AP collection, or time of transplantation until death; the last recorded visit was a censored event. A P-value of less than 0.05 was considered to be significant.
Results
A total of 83 patients who underwent ICT and stem cell collection for breast cancer were examined for expression of cytokeratin-positive cells in their AP. Patients ranged in age from 21 to 65 years (average age 45 years) ( Table 1) . The majority of patients were stage 3 or 4 at the time of transplant. Only 12.0% of patients were stage 2 ( Table 2) .
One AP from each individual was examined for the presence of cytokeratin-positive cells as an indication of contaminating tumor cells. When using an immunofluorescent technique and no other identifying features such as morphology, it is difficult to positively identify a single Having established a cutoff for true significant tumor cell contamination, we next wanted to establish if a positive AP correlated with time to progression. All patient records were obtained. Progression was recorded at the time a relapse was first recorded. We found that there was a highly significant difference in PFS between the AP+ and APÀ groups. Individuals with a positive AP had a significant decrease in PFS from the time of apheresis (Figure 1a , P ¼ 0.0007). This was also true when time to progression was calculated from the time of transplant (Figure 1b , P ¼ 0.007). Both time points were examined as some patients had a longer delay between the time of collection until the time of transplantation (varied from a few weeks to 5 months).
Next we wanted to determine if the presence of micrometastases in APs had an impact on OS. Initially, we examined OS from the time of AP collection. We found there was a significant difference between the AP+ and APÀ groups (P ¼ 0.038; Figure 2a ). This suggested that the APÀ group represented a poor prognosis group. This held true when OS from the time of transplantation was examined (P ¼ 0.048, Figure 2b) . Interestingly, when we examined OS from the time of initial diagnosis, we found no difference between the two groups (P ¼ 0.2) (Figure 3 ). This suggested that the two groups were equivalent. The time from diagnosis to death may include the period from early stage to developing metastasis. This might be anywhere between a few weeks and many years. In the case of initial stage IV there may actually be a very short period time between diagnosis and the time of HDCT and ASCT. The AP is performed just a few weeks prior to HDCT. Therefore, it is not surprising that there is no correlation between the AP contamination and OS from time of diagnosis. There was also no significant difference in time to transplant between the two groups (17.0673.1 (p3) vs 25.3710.7 (43) (P ¼ 0.4)).
Finally, to ensure that the 43 group did not consist of more stage IV patients and this is why the group had a poorer prognosis, a subset analysis of stage IV patients was performed. We found that PFS was significantly different between the two groups (P ¼ 0.006). OS was also significantly different when one substantial outlier was removed from the group (P ¼ 0.04). Deaths in both the APÀ and AP+ groups were divided, with 14% of the deaths contributing to stage III patients and 85% to stage IV patients.
Discussion
HDCT with subsequent autologous peripheral stem cell transplantation (PSCT) has been extensively used for the treatment of hematologic malignancies and also in some selected solid tumors. [16] [17] [18] [19] [20] [21] Although between 40 and 60% of complete responses have been observed, [16] [17] [18] [19] concern. It may lead to recurrences in patients who, after HDCT, achieved a complete remission. Therefore, establishing a sensitive and specific test for the detection of breast cancer cells in PBSC is important. To date, a number of studies in the adjuvant setting using these techniques are still underway and may show benefit once fully evaluated. For patients with advanced/metastatic breast cancer, this treatment did not show survival benefit and will not be used as a treatment option in the future.
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The presence of cancer cells in autografts of patients with breast cancer has been described to be of either prognostic value or directly leading to relapse. We have shown in a previous study that APs collected after the second or third cycle of ICT carry a significantly lower likelihood of tumor cell contamination. 25 In this study, we explore the prognostic potential of micrometastasis in the autografts. Data from 83 patients with breast cancer, who were treated with HDCT and ABSCT, were analyzed. All patients who responded to ICT were treated with one additional cycle of CT plus G-CSF until apheresis was completed. Pancytokeratin-FITC conjugated antibodies with appropriate controls were used to detect contaminating breast cancer cells in the APs by flow cytometry. It was important to examine tumor cell contamination of APs as the tumor cell contamination of stem cells harvested cannot be safely predicted by a preceding blood or marrow analysis. 26 Of the 83 patients examined, 13.3% (11) had a positive AP. This is consistent with findings of tumor cell contamination as determined in other studies. 3, 27 In another study, tumor cells were detected in 10% of patients (BM, blood and AP together). This rate of tumor cell contamination was not dependent upon the method of mobilization (GCSF or GSCF+SCF). 28 When we analyzed our progression and survival data based on three or less contaminating cancer cells, they were not found to be significantly different. Not until a cut off of 43 tumor cells/slide was used was a significant difference noted. This was not surprising, suggesting that contamination of o3 tumor cells/slide may not represent true tumor cell contamination, but rather false positives. At 43 one is confident that there are micrometastases actually present in the AP. Examination of 1, 2, and 3 positive cells demonstrated that these were not statistically significant. This could suggest that 1-2 cells may be real contaminating cells but they do not carry any clinical significance. It is not clear from this study if the micrometastases are what is causing the relapse, or if the micrometastases detected merely represent a higher level of minimal residual disease.
Having established a level of significance indicating contamination of tumor cells, we found that individuals with positive AP had both shorter PFS and OS. This shorter OS suggested that individuals with positive AP might represent a poor prognosis group. Positive AP results correlated with high tumor state or burden. 29 Both subsets (AP+ and APÀ) consisted of stage II, III, and IV patients. The sample size of the AP+ was too small to perform a multivariate analysis based upon stage. However, when we examined stage IV patients separately, we saw a significant difference between the OS for AP+ and APÀ populations. We conclude therefore that APÀnegative patients may represent a group with a better prognosis and perhaps are more appropriate to transplant. This group appeared less likely to quickly progress and have a significant increase in OS.
